Greenwood Capital Associates’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-37,958
| Closed | -$2.78M | – | 238 |
|
|
2024
Q1 | $2.78M | Buy |
37,958
+2,905
| +8% | +$223K | 0.37% | 76 |
|
|
2023
Q4 | $2.84M | Sell |
35,053
-55
| -0.2% | -$4.28K | 0.37% | 78 |
|
|
2023
Q3 | $2.63M | Sell |
35,108
-2
| -0% | -$154 | 0.38% | 79 |
|
|
2023
Q2 | $2.71M | Buy |
35,110
+1,430
| +4% | +$114K | 0.38% | 71 |
|
|
2023
Q1 | $2.79M | Buy |
33,680
+4,069
| +14% | +$337K | 0.4% | 70 |
|
|
2022
Q4 | $2.54M | Sell |
29,611
-8,276
| -22% | -$655K | 0.42% | 63 |
|
|
2022
Q3 | $2.34M | Buy |
37,887
+1,486
| +4% | +$93.7K | 0.4% | 64 |
|
|
2022
Q2 | $2.25M | Buy |
36,401
+1,758
| +5% | +$109K | 0.36% | 68 |
|
|
2022
Q1 | $2.06M | Buy |
34,643
+17,476
| +102% | +$1.12M | 0.54% | 38 |
|
|
2021
Q4 | $1.25M | Buy |
17,167
+4,799
| +39% | +$331K | 0.18% | 103 |
|
|
2021
Q3 | $864K | Buy |
12,368
+5,229
| +73% | +$367K | 0.13% | 124 |
|
|
2021
Q2 | $492K | Buy |
+7,139
| New | +$477K | 0.07% | 182 |
|
|
2020
Q3 | – | Sell |
-45,486
| Closed | -$3.5M | – | 190 |
|
|
2020
Q2 | $3.5M | Sell |
45,486
-16,348
| -26% | -$1.25M | 0.8% | 49 |
|
|
2020
Q1 | $4.62M | Sell |
61,834
-32,531
| -34% | -$2.25M | 1.36% | 30 |
|
|
2019
Q4 | $6.13M | Buy |
94,365
+27,345
| +41% | +$1.78M | 1.29% | 25 |
|
|
2019
Q3 | $4.25M | Buy |
67,020
+4,155
| +7% | +$272K | 1.03% | 39 |
|
|
2019
Q2 | $4.25M | Buy |
+62,865
| New | +$4.14M | 1.07% | 38 |
|
|
2018
Q2 | – | Sell |
-54,911
| Closed | -$4.14M | – | 206 |
|
|
2018
Q1 | $4.14M | Sell |
54,911
-16,439
| -23% | -$1.31M | 1.01% | 42 |
|
|
2017
Q4 | $5.11M | Sell |
71,350
-8,859
| -11% | -$673K | 1.19% | 29 |
|
|
2017
Q3 | $6.5M | Buy |
80,209
+49,653
| +162% | +$3.8M | 1.62% | 13 |
|
|
2017
Q2 | $2.16M | Buy |
30,556
+4,386
| +17% | +$292K | 0.56% | 74 |
|
|
2017
Q1 | $1.78M | Buy |
26,170
+1,126
| +4% | +$79.2K | 0.47% | 83 |
|
|
2016
Q4 | $1.79M | Buy |
25,044
+655
| +3% | +$48.7K | 0.51% | 77 |
|
|
2016
Q3 | $1.93M | Sell |
24,389
-611
| -2% | -$49.6K | 0.59% | 73 |
|
|
2016
Q2 | $2.09M | Sell |
25,000
-355
| -1% | -$31.5K | 0.64% | 72 |
|
|
2016
Q1 | $2.33M | Sell |
25,355
-1,224
| -5% | -$110K | 0.73% | 60 |
|
|
2015
Q4 | $2.69M | Buy |
26,579
+998
| +4% | +$104K | 0.87% | 46 |
|
|
2015
Q3 | $2.51M | Sell |
25,581
-2,852
| -10% | -$317K | 0.89% | 48 |
|
|
2015
Q2 | $3.33M | Sell |
28,433
-1,834
| -6% | -$200K | 1.01% | 45 |
|
|
2015
Q1 | $2.97M | Sell |
30,267
-1,333
| -4% | -$135K | 0.85% | 49 |
|
|
2014
Q4 | $2.98M | Sell |
31,600
-378
| -1% | -$39.1K | 0.86% | 49 |
|
|
2014
Q3 | $3.4M | Buy |
31,978
+15
| +0% | +$1.47K | 1.04% | 45 |
|
|
2014
Q2 | $2.65M | Sell |
31,963
-498
| -2% | -$38.8K | 0.82% | 50 |
|
|
2014
Q1 | $2.3M | Sell |
32,461
-64,294
| -66% | -$5.04M | 0.74% | 64 |
|
|
2013
Q4 | $7.27M | Sell |
96,755
-14,927
| -13% | -$1.04M | 2.26% | 5 |
|
|
2013
Q3 | $7.02M | Sell |
111,682
-3,830
| -3% | -$229K | 2.48% | 3 |
|
|
2013
Q2 | $5.92M | Buy |
+115,512
| New | +$6.02M | 2.57% | 5 |
|
Other funds holding GILD
Greenwood Capital Associates's GILD Position: Q2 2024 in Review
Greenwood Capital Associates sold out of Gilead Sciences (GILD) in Q2 2024, closing a stake of 37,958 shares — an estimated $2.78M sold.
Greenwood Capital Associates first reported a position in GILD in Q2 2013 and held it in 37 quarters. The position peaked at $7.27M in Q4 2013. 1,679 funds tracked by Wall St. Rank hold GILD as of Q2 2024.
- Greenwood Capital Associates reported no remaining Gilead Sciences position as of Q2 2024 after selling out during the quarter.
- Greenwood Capital Associates sold 37,958 Gilead Sciences shares in Q2 2024, an estimated $2.78M.
- Greenwood Capital Associates first reported a position in Gilead Sciences in Q2 2013 and held it in 37 quarters.
- Greenwood Capital Associates's Gilead Sciences position peaked at $7.27M in Q4 2013.
- 1,679 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.
Based on Greenwood Capital Associates's 13F filing for Q2 2024, filed 8 Aug 2024.